Targeting MET in NSCLC: An Ever-Expanding Territory

JTO Clin Res Rep. 2024 Jan 3;5(2):100630. doi: 10.1016/j.jtocrr.2023.100630. eCollection 2024 Feb.


MET protooncogene (MET) alterations are known driver oncogenes in NSCLC. Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody-drug conjugates now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers. Although clinical agents are currently available and numerous other options are in development, particular challenges in the field require attention. For example, the therapeutic efficacy of each drug remains unsatisfactory, and concomitantly, the resistance mechanisms are not fully understood. Thus, there is an urgent need for optimal drug sequencing and combinations, along with a thorough understanding of treatment resistance. In this review, we describe the current landscape of pertinent clinical trials focusing on MET-targeted strategies and discuss future developmental directions in this rapidly expanding field.

Keywords: Antibody-drug conjugate; MET; Monoclonal antibodies; Non–small cell lung cancer; Tyrosine kinase inhibitor.

Publication types

  • Review